Patents by Inventor Michael J. Abrams

Michael J. Abrams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260137822
    Abstract: Described herein are immunoconjugates comprising a multivalent antibody and a chelating agent, wherein the multivalent antibody comprises a polypeptide comprising: a first antigen-binding domain; and a second antigen-binding domain.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 21, 2026
    Inventors: Michael J. ABRAMS, Emma Jane CUMMINS, Adam Daniel JUDGE, Alexander Laurence MANDEL, Raja Solomon VISWAS
  • Patent number: 12600794
    Abstract: Described herein are polypeptides that bind to 5T4 useful for cancer therapy. Further disclosed herein are polypeptides that bind to 5T4 that are conjugated to a chelating agent or a radionuclide complex thereof.
    Type: Grant
    Filed: July 21, 2025
    Date of Patent: April 14, 2026
    Assignee: ABDERA THERAPEUTICS INC.
    Inventors: Alexander Laurence Mandel, Raja Solomon Viswas, Adam Daniel Judge, Michael J. Abrams, Emma Jane Cummins, Brandon Robert McLeod, Iva Kulic, Douglas Bruce MacKay
  • Publication number: 20260055180
    Abstract: Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglobulin single-chain domain antibody) and a Fc domain, wherein the antigen-binding domain binds an antigen present within the kidney.
    Type: Application
    Filed: August 21, 2023
    Publication date: February 26, 2026
    Inventors: Michael J. ABRAMS, Emma Jane CUMMINS, Adam Daniel JUDGE
  • Publication number: 20260028414
    Abstract: Described herein are polypeptides that bind to 5T4 useful for cancer therapy. Further disclosed herein are polypeptides that bind to 5T4 that are conjugated to a chelating agent or a radionuclide complex thereof.
    Type: Application
    Filed: July 21, 2025
    Publication date: January 29, 2026
    Inventors: Alexander Laurence MANDEL, Raja Solomon VISWAS, Adam Daniel JUDGE, Michael J. ABRAMS, Emma Jane CUMMINS, Brandon Robert MCLEOD, Iva KULIC, Douglas Bruce MACKAY
  • Publication number: 20250281422
    Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.
    Type: Application
    Filed: May 27, 2025
    Publication date: September 11, 2025
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. ABRAMS, James HEYES, Richard J. HOLLAND, Kieu Mong LAM, Mark WOOD
  • Patent number: 12350383
    Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: July 8, 2025
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. Abrams, James Heyes, Richard J. Holland, Kieu Mong Lam, Mark Wood
  • Patent number: 12344675
    Abstract: Described herein are heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies useful for cancer therapy.
    Type: Grant
    Filed: October 25, 2024
    Date of Patent: July 1, 2025
    Assignee: ABDERA THERAPEUTICS INC.
    Inventors: Michael J. Abrams, Emma Jane Cummins, Adam Daniel Judge, Alexander Laurence Mandel, Raja Solomon Viswas
  • Publication number: 20250051476
    Abstract: Described herein are heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies useful for cancer therapy.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 13, 2025
    Inventors: Michael J. ABRAMS, Emma Jane CUMMINS, Adam Daniel JUDGE, Alexander Laurence MANDEL, Raja Solomon VISWAS
  • Publication number: 20220160899
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 26, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
  • Publication number: 20220133636
    Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 5, 2022
    Inventors: Michael J. ABRAMS, James HEYES, Richard J. HOLLAND, Kieu Mong LAM, Mark WOOD
  • Publication number: 20220016127
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in inducing reparative regeneration and/or appendage regeneration. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of one or more amino acids and a therapeutically effective amount of one or more sugars, and thereby inducing reparative regeneration or appendage regeneration in the subject. There are provided, in some embodiments, regenerative agents suitable for use in the methods provided herein. Regenerative agents can stimulate mTOR signaling and/or insulin signaling. Regenerative agents can include one or more amino acids, insulin, and/or one or more sugars.
    Type: Application
    Filed: June 23, 2021
    Publication date: January 20, 2022
    Inventors: Lea Goentoro, Michael J. Abrams, Fayth Tan, Martin Heithe, Ty Basinger
  • Patent number: 11191849
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 7, 2021
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. Abrams, James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Stephen P. Reid, Edward D. Yaworski
  • Publication number: 20190240354
    Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 8, 2019
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
  • Publication number: 20190216773
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Application
    Filed: August 21, 2018
    Publication date: July 18, 2019
    Inventors: Gary J. BRIDGER, Michael J. ABRAMS, Geoffrey W. HENSON, Ronald Trevor MACFARLAND, Gary B. CALANDRA, Hal E. BROXMEYER, David C. DALE
  • Publication number: 20170049747
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Application
    Filed: March 18, 2016
    Publication date: February 23, 2017
    Inventors: Gary J. BRIDGER, Michael J. ABRAMS, Geoffrey W. HENSON, Ronald Trevor MACFARLAND, Gary B. CALANDRA, Hal E. BROXMEYER, David C. DALE
  • Publication number: 20150246019
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Application
    Filed: October 3, 2014
    Publication date: September 3, 2015
    Inventors: Gary J. BRIDGER, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor Macfarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
  • Publication number: 20110129448
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 2, 2011
    Applicant: Genzyme Corporation
    Inventors: Gary J. BRIDGER, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
  • Patent number: 7935692
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: May 3, 2011
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
  • Patent number: 7897590
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: March 1, 2011
    Assignee: Genzyme Corporation
    Inventors: Gary J. Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald Trevor MacFarland, Gary B. Calandra, Hal E. Broxmeyer, David C. Dale
  • Patent number: 7192609
    Abstract: Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: March 20, 2007
    Assignee: Shire International Licensing B.V.
    Inventors: Michael J. Abrams, Gary J. Bridger, Simon P. Fricker, Stefan R. Idzan